BETA
Your AI-Trained Oncology Knowledge Connection!
Learning AE Management With Immunotherapy vs TKIs in RCC
Hans Hammers, MD, and his team discuss the most pertinent treatment options for patients with renal cell carcinoma.
HER2-Related Biomarkers Confer Response to T-DXd in Advanced Gastric Cancer
Higher response rates with T-DXd occurred in patients with gastric cancer and plasma HER2 amplification in circulating tumor DNA in the DESTINY-Gatric01 trial.
49 The Influence of Race on Complications in Breast Conservation Surgery: A Single Institution Study
Vepdegestrant Combo Shows Clinical Activity in ER+/HER2– Breast Cancer
Phase 1b data support the promising therapeutic benefit of vepdegestrant/palbociclib in ER-positive breast cancer regardless of ESR1 mutation status.
Nivolumab/Relatlimab Shows Feasibility in Resectable NSCLC
The NEOpredict-Lung trial met its primary end point with nivolumab plus relatlimab for patients with resectable non–small cell lung cancer.
Developers Submit BLA for Tabelecleucel in EBV+ Lymphoproliferative Disease
Data from the ALLELE trial support the application for tabelecleucel in patients with EBV-positive post-transplant lymphoproliferative disease.
Inavolisib Earns FDA Breakthrough Therapy Designation in Breast Cancer
Data from the INAVO120 trial support the breakthrough therapy designation for inavolisib in PIK3CA-mutated, HR-positive, HER2-negative breast cancer.
Exploring the Benefits and Risks of AI in Oncology
Ted A. James, MD, MHCM, FACS, spoke about integrating artificial intelligence into oncology care.
Incorporating the Emerging Field of Exercise Oncology into Breast Cancer Care
Neil M. Iyengar, MD, spoke about the importance of exercise oncology and how it may play a role in positive treatment outcomes for breast cancer.
FDA Withdraws Infigratinib Approval Status in FGFR2+ Cholangiocarcinoma
Developers voluntarily request withdrawal of accelerated approval status for infigratinib as a treatment for FGFR2-positive cholangiocarcinoma.
Expert Commentary on the Product Profile of Enfortumab Vedotin Plus Pembrolizumab
Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, gives his perspective on the approval of enfortumab vedotin plus pembrolizumab for patients with urothelial carcinoma.
FDA Sends CRL for Camrelizumab/Rivoceranib in Unresectable Liver Cancer
The agency issues a complete response letter for the combination due to deficiencies associated with a manufacturing site inspection.
Finding a Place for Exercise Oncology in the Treatment of Breast Cancer
Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.
50 Nipple Sparing Mastectomy With Immediate Lift Using Vertical Technique: Our Initial Experience
Scratching the Surface in Managing Advanced RCC
Matthew T. Campbell, MD, MS, discusses CAR T-cell therapy and immunotherapy advances in renal cell carcinoma.
51 Ductal Carcinoma In Situ With Microinvasion on Biopsy—What Are the Predictors of Upstaging?
Exciting New Treatment Updates Are on the Horizon for Advanced RCC
Moshe Ornstein, MD, highlights recent treatment updates for renal cell carcinoma.
52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy
VEN-HMA May Prolong Survival in Elderly Acute Myeloid Leukemia Population
A reduced dosing duration of venetoclax plus hypomethylating agents may be appropriate for elderly patients with acute myeloid leukemia.
NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC
Data from the phase 1/2 ALKOVE-1 trial support the breakthrough therapy designation for NVL-655 in advanced ALK-positive non–small cell lung cancer.
AI Use in Prostate Cancer: Potential Improvements in Treatments and Patient Care
Artificial intelligence use in prostate cancer encompasses 4 main areas including diagnostic imaging, prediction of outcomes, histopathology, and treatment planning.
FDA Approves Tarlatamab After Progression on Chemotherapy in ES-SCLC
The phase 2 DELLphi-301 trial showed durable response rates when tarlatamab was used to treat extensive-stage small cell lung cancer.
53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ
Dato-DXd Shows Improved Tolerability Vs Chemo in HR+/HER2– Breast Cancer
Safety data further support datopotamab deruxtecan as a new treatment option in metastatic hormone receptor–positive, HER2-negative breast cancer.
Ovarian Cancer Linked to Genital Talcum Powder Use
Results of the Sister Study cohort found an increased risk of ovarian cancer when enrolled patients used genital talcum powder throughout young adulthood.
Synchronous Well-Differentiated Papillary Mesothelioma and Endometrioid Adenocarcinoma Arising From Endometriosis
Learn more about a 56-year-old woman diagnosed with well-differentiated papillary mesothelioma, and how she was diagnosed and properly treated.
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
Liso-cel Earns FDA Accelerated Approval in R/R Follicular Lymphoma
Data from the TRANSCEND-FL trial support the accelerated approval of lisocabtagene maraleucel in relapsed/refractory follicular lymphoma.
Pre-Transplant FLT3-ITD Detection Confers Relapse/Death Risk in AML
Alternative treatment strategies may be necessary for a high-risk population of patients with acute myeloid leukemia and residual FLT3-ITD.
FDA Grants Breakthrough Therapy Designation to Petosemtamab in HNSCC
Data from a phase 1/2 trial support the FDA breakthrough therapy designation for petosemtamab in recurrent head and neck squamous cell carcinoma.
